Cellectar Biosciences to Announce Financial Results
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a biopharmaceutical company devoted to the development of innovative cancer treatments, is getting ready to share its financial results for the year ending December 31, 2024. This important announcement is scheduled for March 13, 2025, at 8:30 a.m. Eastern Time. This is a momentous occasion for the company as it not only reflects its financial standing but provides an opportunity to highlight upcoming corporate advancements.
Details of the Conference Call
The financial results announcement will be accompanied by a conference call and webcast. The specifics are as follows:
- Date: Thursday, March 13, 2025
- Time: 8:30 a.m. Eastern Time
- Toll Free Number: 1-800-717-1738
- Conference ID: 25759
A link to the webcast will also be available, enabling all interested parties to engage in the discussion.
About Cellectar Biosciences
Cellectar Biosciences stands at the forefront of the biopharmaceutical industry, focusing specifically on cancer treatment solutions. Their aim is clear: to discover and develop proprietary drugs that target cancer cells effectively while minimizing side effects. Utilizing their proprietary Phospholipid Drug Conjugate™ (PDC) platform, they are making significant strides in cancer therapeutics.
Innovative Product Pipeline
The company's impressive pipeline includes several noteworthy assets including:
- iopofosine I 131: A PDC utilizing targeted delivery of iodine-131, designed to enhance treatment effects in various cancer types.
- CLR 121225: An actinium-225 program aimed at addressing solid tumors that pose significant treatment challenges, such as pancreatic cancer.
- CLR 121125: Using iodine-125, this program focuses on other aggressive cancers such as triple-negative breast cancer, colorectal cancer, and lung cancer.
- Additionally, the company is developing several preclinical PDC chemotherapeutic programs and partnering with organizations to expand its reach.
Cellectar’s flagship asset, iopofosine I 131, is currently undergoing Phase 2b trials for conditions like relapsed multiple myeloma and CNS lymphoma. This drug is even eligible to receive a Pediatric Review Voucher from the FDA upon regulatory approval, highlighting its potential impact on pediatric oncology.
Regulatory Designations
The company’s commitment to innovation has not gone unnoticed; the FDA has awarded iopofosine I 131 several designations, including six Orphan Drug designations, four Rare Pediatric Drug designations, and two Fast Track Designations. These accolades underline the product's promising potential in the fight against various cancers.
Staying Connected with Investors
Cellectar Biosciences emphasizes transparency and open communication with its investors. They encourage individuals to visit their website for more information and updates about the company's progress.
Investor Contact:
Anne Marie Fields
212-362-1200
Precision AQ (formerly Stern IR)
Email: annemariefields@precisionaq.com
Frequently Asked Questions
What will Cellectar report on March 13, 2025?
Cellectar will announce its financial results for the year ending December 31, 2024, and provide a corporate update.
How can I access the conference call?
You can access the call by dialing the toll-free number provided, with a conference ID to join the discussion.
What is the focus of Cellectar Biosciences?
The company specializes in developing proprietary drugs for cancer treatment, utilizing their unique drug delivery platform.
What designations has iopofosine I 131 received?
It has garnered multiple designations from the FDA, including Orphan Drug and Fast Track Designations.
Who is the contact person for investor inquiries?
Anne Marie Fields is the designated contact for any investor-related questions or concerns.
